A Phase 2a, Randomized, Participant- and Investigator- Blinded, Parallel-group, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With DSM-5 Schizophrenia (STAR-1)
Latest Information Update: 24 Mar 2026
At a glance
- Drugs GXV 813 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms STAR-1
- Sponsors Novartis
Most Recent Events
- 20 Mar 2026 Status changed from not yet recruiting to recruiting.
- 17 Mar 2026 New trial record